|1.||Field, Hugh J: 3 articles (08/2009 - 07/2007)|
|2.||Biswas, Subhajit: 3 articles (08/2009 - 07/2007)|
|3.||Kleymann, Gerald: 3 articles (02/2008 - 06/2002)|
|4.||Rübsamen-Waigmann, Helga: 2 articles (02/2008 - 06/2002)|
|5.||Itzhaki, R F: 1 article (09/2013)|
|6.||Wozniak, M A: 1 article (09/2013)|
|7.||Frost, A L: 1 article (09/2013)|
|8.||Miguel, Ricardo Núñez: 1 article (08/2009)|
|9.||Sukla, Soumi: 1 article (08/2009)|
|10.||De Clercq, Erik: 1 article (09/2008)|
01/01/2007 - "Finally, in a study addressing the treatment of recurrent disease in animals whose primary infection had remained untreated BAY 57-1293 was efficient in suppressing the episodes. "
09/01/2013 - "Also, the cell clusters that are formed during infection are reduced in size much more efficiently by BAY 57-1293 than by ACV. "
08/01/2009 - "The variant was approximately 40-fold resistant to the HPI BAY 57-1293 and it showed significantly reduced growth in tissue culture with a concomitant reduction in virulence in a murine infection model. "
01/01/2007 - "Early therapy with BAY 57-1293 almost completely suppressed the symptoms of acute HSV-2 infection, and reduced virus shedding and viral load in the sacral dorsal root ganglia by up to three orders of magnitude, resulting in decreased latency and a greatly diminished frequency of subsequent recurrent episodes. "
06/01/2002 - "In various rodent models of HSV infection the antiviral activity of BAY 57-1293 in vivo was found to be superior compared to all compounds currently used to treat HSV infections. "
|5.||Herpes Genitalis (Genital Herpes)
01/01/2007 - "The efficacy of BAY 57-1293, a novel non-nucleosidic inhibitor of herpes simplex virus 1 and 2 (HSV-1 and HSV-2), bovine herpesvirus and pseudorabies virus, was studied in the guinea pig model of genital herpes in comparison with the licensed drug valaciclovir (Valtrex). "
01/01/2007 - "In summary, superior potency and efficacy of BAY 57-1293 over standard treatment with valaciclovir was demonstrated in relevant animal models of human genital herpes disease in terms of abrogating an HSV infection, reducing latency and the frequency of subsequent recurrences. "
01/01/2007 - "Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease."
|1.||DNA Primase (Primase)
|2.||Antiviral Agents (Antivirals)
|3.||Ophthalmic Solutions (Eye Drops)
|6.||Reverse Transcriptase Inhibitors
|8.||RNA Replicase (RNA Dependent RNA Polymerase)
|9.||Protease Inhibitors (Protease Inhibitor)